OGN

Organon & Co.

Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. Organon sells to international markets.

Organon & Co. (OGN) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (C-). The rating has held at C+ for 10 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B
Factor Score 3.2 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 17.8
EV / EBITDA 6.9
Rev Growth YoY -1.7%
Gross Margin 53.6%
Price Return 3M 1.5%
Price Return 12M 86.6%
Catalyst Signal 0.00
Market Cap $3.7B
TTM Revenue $6.1B
Price / Sales 0.6
ROE 20.3%

Historical Factor Score Progression

Held C+ for 10 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B (3.2) C- (1.9) B- (3.0) B (3.2) C+ (2.6) C+ (2.8)
2026-11-06 B (3.2) C- (1.9) B- (3.0) B (3.2) C+ (2.7) C+ (2.8)
2026-10-30 B (3.2) D+ (1.7) B- (3.0) B- (3.0) C+ (2.7) C+ (2.7)
2026-10-23 B (3.2) D+ (1.7) B- (3.0) B+ (3.5) C+ (2.6) C+ (2.8)
2026-10-16 B (3.2) D+ (1.8) B- (3.0) B (3.4) C+ (2.6) C+ (2.8)
Page 1 of 3